NVCR News and Press, NovoCure Limited From 04/29/21

NovoCure (NVCR): Q1 GAAP EPS of -$0.04 misses by $0.06.Revenue of $134.7M (+32.3% Y/Y) misses by $3.41M.There were 3,454 active patients at March 31, 2021, representing 12% growth compared to March 31, 2020, and 1% growth compared to December 31, 2020.Press Release For further details see: ...

Quarterly net revenues of $134.7 million with 80% gross margin Interim analysis for phase 3 pivotal LUNAR trial in non-small cell lung cancer concluded with favorable recommendation to continue the trial with reduced sample size Novocure (NASDAQ: NVCR) today reported...

NovoCure (NASDAQ:NVCR) is scheduled to announce Q1 earnings results on Thursday, April 29th, before market open.The consensus EPS Estimate is $0.01 and the consensus Revenue Estimate is $138.11M (+35.6% Y/Y).Over the last 1 year, NVCR has beaten EPS estimates 25% of the time and has beaten re...

Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) application to initiate the KEYNOTE-B36 trial, conducted in collaboration with MSD (Merck & Co., Inc., Kenilworth, NJ, USA). Novocure also...

On April 13, Novocure (NASDAQ: NVCR) stock jumped after the company received a green light to accelerate a pivotal phase 3 study. The investigation involves its medical device, Optune, to treat advanced-stage non-small-cell lung cancer (NSCLC). Optune is a portable device ...

Novocure (NASDAQ: NVCR) hasn't exactly been the kind of stock that fired up investors very much throughout most of 2021. That changed recently, though, with good news providing a huge catalyst for the stock. In this Motley Fool Live video recorded on April 14, 2021 , Motley ...

Insider buying increased significantly last week. Notable Insider Buys: Landec Corporation, Super League Gaming, Inc., Cyclo Therapeutics, Inc., Greenwich LifeSciences, Inc., and Hudson Global, Inc. Notable Insider Sells: Ulta Beauty, Inc., Facebook, Inc., Fidelity National Financ...

NovoCure continues to build out its product suite. The company is pivoting towards new indications which greatly expands the overall market. I think further expansion of its addressable market especially into non-small cell lung cancer should lead to an acquisition. For furt...

Novocure (NASDAQ: NVCR) has been on a tremendous run -- up 17 times over the last five years -- leaving many investors thinking that they missed the boat. But in investing, winners keep on winning. Recent news in the lung cancer treatment area for Novocure's Optune, a wearab...

Yesterday, Novocure's stock price made a huge jump of 50% because of an update of its LUNAR study. We look at the history of the company and the key people. Novocure already has 3 FDA approvals, 2 for glioblastoma and 1 for mesothelioma, but its total addressable market is much bi...